DK1583529T3 - Aminosyre-phenoxy-ethere, fremstilling og anvendelse deraf - Google Patents

Aminosyre-phenoxy-ethere, fremstilling og anvendelse deraf

Info

Publication number: DK1583529T3
Authority: DK; Denmark
Prior art keywords: amino acid; preparation; acid phenoxy; phenoxy ethers; ethers
Prior art date: 2003-01-17

Application number

DK04701752.0T

Other languages

English (en)

Inventor

Bishwajit Nag

Abhijeet Nag

Debendranath Dey

Shiv Kumar Agarwal

Original Assignee

Bexel Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-17

Filing date

2004-01-13

Publication date

2012-01-23

2004-01-13 Application filed by Bexel Pharmaceuticals Inc filed Critical Bexel Pharmaceuticals Inc

2012-01-23 Application granted granted Critical

2012-01-23 Publication of DK1583529T3 publication Critical patent/DK1583529T3/da

Links

-1 Amino acid phenoxy ethers Chemical class 0.000 title abstract 2
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

DK04701752.0T 2003-01-17 2004-01-13 Aminosyre-phenoxy-ethere, fremstilling og anvendelse deraf DK1583529T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US44077203P	2003-01-17	2003-01-17
US10/356,113 US6794401B2 (en)	2003-01-17	2003-01-31	Amino acid phenoxy ethers
PCT/US2004/000790 WO2004066964A2 (en)	2003-01-17	2004-01-13	Amino acid phenoxy ethers

Publications (1)

Publication Number	Publication Date
DK1583529T3 true DK1583529T3 (da)	2012-01-23

Family

ID=32716922

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04701752.0T DK1583529T3 (da)	2003-01-17	2004-01-13	Aminosyre-phenoxy-ethere, fremstilling og anvendelse deraf

Country Status (20)

Country	Link
US (2)	US6794401B2 (da)
EP (1)	EP1583529B9 (da)
JP (1)	JP4833072B2 (da)
KR (1)	KR101085315B1 (da)
AT (1)	ATE532510T1 (da)
AU (1)	AU2004207449A1 (da)
BR (1)	BRPI0406772B1 (da)
CA (1)	CA2513496C (da)
CY (1)	CY1112673T1 (da)
DK (1)	DK1583529T3 (da)
EA (1)	EA200501078A1 (da)
ES (1)	ES2374724T3 (da)
MA (1)	MA27658A1 (da)
MX (1)	MXPA05007684A (da)
NO (1)	NO330984B1 (da)
NZ (1)	NZ541328A (da)
PT (1)	PT1583529E (da)
SI (1)	SI1583529T1 (da)
TW (1)	TWI325420B (da)
WO (1)	WO2004066964A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7521465B2 (en) *	2003-01-17	2009-04-21	Bexel Pharmaceuticals, Inc.	Diphenyl ether derivatives
US7781464B2 (en) *	2003-01-17	2010-08-24	Bexel Pharmaceuticals, Inc.	Heterocyclic diphenyl ethers
US7087576B2 (en) *	2003-10-07	2006-08-08	Bexel Pharmaceuticals, Inc.	Dipeptide phenyl ethers
US7592486B2 (en) *	2004-09-16	2009-09-22	Board Of Regents Of The University Of Nebraska	Anhydrous fluoride salts and reagents and methods for their production
CA2601884A1 (en) *	2005-03-18	2006-09-21	Surendrakumar Satyanarayan Pandey	Novel tyrosine derivatives
US20090203744A1 (en) *	2005-07-29	2009-08-13	Pande Y Surendrakumar Satyanarayan	Novel pyridine derivatives
WO2008019306A2 (en) *	2006-08-04	2008-02-14	Decode Genetics Ehf	Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
US20090005381A1 (en) *	2007-06-26	2009-01-01	Philip Manton Brown	Methods of treating serotonin-mediated diseases and disorders
KR20100046189A (ko)	2007-07-11	2010-05-06	렉시컨 파마슈티컬스 인코퍼레이티드	폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
WO2009030968A1 (en) *	2007-09-05	2009-03-12	Orchid Research Laboratories Limited	Mao a inhibitors with a diphenyl ether-substructure.
EP2300446B1 (en) *	2008-05-20	2011-12-07	Merck Sharp & Dohme Corp.	Efficient production of heterologous proteins using mannosyl transferase inhibitors
CN103108634B (zh)	2010-07-28	2015-08-12	幽兰化学医药有限公司	用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物
WO2012153775A1 (ja)	2011-05-10	2012-11-15	国立大学法人神戸大学	Ras機能阻害作用を有するチオキソチアゾリジン誘導体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020049240A1 (en) *	1994-12-19	2002-04-25	Beecham Group P.1.C.	Novel compounds
US5166137A (en) *	1991-03-27	1992-11-24	Nobipols Forskningsstiftelse	Guluronic acid polymers and use of same for inhibition of cytokine production
US5441971A (en) *	1991-04-11	1995-08-15	The Upjohn Company	Thiazolidinedione derivatives, production and use thereof
EP0590793B1 (en) *	1992-08-31	1999-10-13	Sankyo Company Limited	Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
TW268952B (da) *	1993-02-26	1996-01-21	Takeda Pharm Industry Co Ltd
DK0719140T3 (da) *	1993-09-15	2008-03-03	Daiichi Sankyo Co Ltd	Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM
US5527546A (en) *	1994-08-10	1996-06-18	Bayer Corporation	Human interleukin 6 inhibitor
DE4432101A1 (de) *	1994-09-09	1996-03-14	Hoechst Ag	Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DK0824588T3 (da) *	1995-05-11	2004-08-16	Applied Research Systems	Inhibitor af IL-6 aktivitet
CZ293016B6 (cs) *	1995-06-01	2004-01-14	Sankyo Company Limited	Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
TW577875B (en) *	1997-01-31	2004-03-01	Shionogi & Co	Pyrrolidine derivatives with inhibitory activity for phospholipase A2
JPH11124331A (ja) *	1997-08-21	1999-05-11	Takeda Chem Ind Ltd	抗炎症剤
US6331633B1 (en) *	1998-05-08	2001-12-18	Calyx Therapeutics Inc.	Heterocyclic analogs of diphenylethylene compounds
US6699896B1 (en) *	1998-05-12	2004-03-02	Wyeth	Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
KR20010052615A (ko) *	1998-06-05	2001-06-25	다비드 에 질레스	옥사졸리디논 유도체, 이것의 제조 방법 및 이것을함유하는 약학 조성물
AU5443499A (en) *	1998-08-27	2000-03-21	Ono Pharmaceutical Co. Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
IL145922A0 (en)	1999-04-28	2002-07-25	Aventis Pharma Gmbh	Di-aryl acid derivatives as ppar receptor ligands
TWI284533B (en) *	1999-05-24	2007-08-01	Sankyo Co	Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
AU6340600A (en)	1999-07-01	2001-01-22	Geron Corporation	Telomerase inhibitors and methods of their use
WO2001014349A1 (en) *	1999-08-23	2001-03-01	Kyorin Pharmaceutical Co., Ltd.	Substituted benzylthiazolidine-2,4-dione derivatives
BR0013671A (pt) *	1999-08-31	2003-06-10	Maxia Pharmaceuticals Inc	Derivados heterocìclicos para o tratamento do diabetes e outras doenças
JP2001199888A (ja) *	2000-01-24	2001-07-24	Fujimoto Brothers:Kk	糖尿病治療剤
JP2001294537A (ja) *	2000-02-10	2001-10-23	Takeda Chem Ind Ltd	併用医薬
ATE310733T1 (de)	2000-04-21	2005-12-15	Pfizer Prod Inc	Thyroid-rezeptorliganden
US6680387B2 (en) *	2000-04-24	2004-01-20	Aryx Therapeutics	Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

2003
- 2003-01-31 US US10/356,113 patent/US6794401B2/en not_active Expired - Lifetime
2004
- 2004-01-13 EA EA200501078A patent/EA200501078A1/ru unknown
- 2004-01-13 EP EP04701752A patent/EP1583529B9/en not_active Expired - Lifetime
- 2004-01-13 BR BRPI0406772A patent/BRPI0406772B1/pt not_active IP Right Cessation
- 2004-01-13 CA CA2513496A patent/CA2513496C/en not_active Expired - Fee Related
- 2004-01-13 AU AU2004207449A patent/AU2004207449A1/en not_active Abandoned
- 2004-01-13 DK DK04701752.0T patent/DK1583529T3/da active
- 2004-01-13 AT AT04701752T patent/ATE532510T1/de active
- 2004-01-13 PT PT04701752T patent/PT1583529E/pt unknown
- 2004-01-13 ES ES04701752T patent/ES2374724T3/es not_active Expired - Lifetime
- 2004-01-13 NZ NZ541328A patent/NZ541328A/en not_active IP Right Cessation
- 2004-01-13 WO PCT/US2004/000790 patent/WO2004066964A2/en not_active Ceased
- 2004-01-13 SI SI200431804T patent/SI1583529T1/sl unknown
- 2004-01-13 KR KR1020057013193A patent/KR101085315B1/ko not_active Expired - Fee Related
- 2004-01-13 MX MXPA05007684A patent/MXPA05007684A/es active IP Right Grant
- 2004-01-13 JP JP2006536536A patent/JP4833072B2/ja not_active Expired - Fee Related
- 2004-01-14 TW TW093100932A patent/TWI325420B/zh not_active IP Right Cessation
- 2004-09-21 US US10/947,047 patent/US20050096366A1/en not_active Abandoned
2005
- 2005-08-01 NO NO20053714A patent/NO330984B1/no not_active IP Right Cessation
- 2005-08-16 MA MA28444A patent/MA27658A1/fr unknown
2012
- 2012-02-09 CY CY20121100137T patent/CY1112673T1/el unknown

Also Published As

Publication number	Publication date
EP1583529A2 (en)	2005-10-12
WO2004066964A2 (en)	2004-08-12
EA200501078A1 (ru)	2006-02-24
EP1583529B9 (en)	2012-04-04
CY1112673T1 (el)	2016-02-10
WO2004066964A3 (en)	2005-02-24
US20040142991A1 (en)	2004-07-22
BRPI0406772A (pt)	2005-12-27
AU2004207449A1 (en)	2004-08-12
WO2004066964A9 (en)	2004-09-02
TW200418792A (en)	2004-10-01
ATE532510T1 (de)	2011-11-15
NO20053714L (no)	2005-10-11
BRPI0406772B1 (pt)	2016-08-23
US20050096366A1 (en)	2005-05-05
MA27658A1 (fr)	2005-12-01
US6794401B2 (en)	2004-09-21
NZ541328A (en)	2008-11-28
ES2374724T3 (es)	2012-02-21
JP2007501288A (ja)	2007-01-25
MXPA05007684A (es)	2006-03-10
KR101085315B1 (ko)	2011-11-22
TWI325420B (en)	2010-06-01
CA2513496A1 (en)	2004-08-12
PT1583529E (pt)	2012-02-13
EP1583529A4 (en)	2007-07-04
SI1583529T1 (sl)	2012-02-29
CA2513496C (en)	2013-05-14
NO330984B1 (no)	2011-08-29
EP1583529B1 (en)	2011-11-09
NO20053714D0 (no)	2005-08-01
KR20050092764A (ko)	2005-09-22
JP4833072B2 (ja)	2011-12-07

Publication	Publication Date	Title
CY1112673T1 (el)	2016-02-10	Φαινοξυ αιθερες αμινοξεων
DK1651161T3 (da)	2012-01-30	Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
ATE417037T1 (de)	2008-12-15	Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
NO20070782L (no)	2007-04-02	Tetrapeptidanaloger.
EA200800172A1 (ru)	2008-08-29	2,4-диаминопиримидины как ингибиторы aurora
IS7684A (is)	2005-02-03	Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
MXPA05010830A (es)	2005-12-15	Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
SE0301700D0 (sv)	2003-06-10	Novel compounds
ATE515514T1 (de)	2011-07-15	Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
UA85559C2 (en)	2009-02-10	Aminobenzophenone compounds
PL374383A1 (en)	2005-10-17	Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
PL1622939T3 (pl)	2012-08-31	Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
EA200501821A1 (ru)	2006-06-30	Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
UA90698C2 (en)	2010-05-25	Triazole substituted aminobenzophenone compounds
EP2107071A3 (en)	2009-12-30	Anti-EpCAM immunoglobulins
BRPI0509524A (pt)	2007-09-18	formas cristalinas de n-desmetilclozapina
NO20052203D0 (no)	2005-05-04	Anvendelse av cytokin som kan binde IL-18BP og inhibere aktiviteten til et andre cytokin
CY1105105T1 (el)	2009-11-04	Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων
UA92013C2 (en)	2010-09-27	Novel indoline compounds
ATE392213T1 (de)	2008-05-15	Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
WO2004056762A3 (en)	2004-08-12	Novel aminobenzophenone compounds
EA200500624A1 (ru)	2005-10-27	Промотор для il-18bp, его получение и применение
AU2013204147B2 (en)	2015-09-03	Treatment of TNFalpha related disorders
SE0202287D0 (sv)	2002-07-19	New compounds
ITMI20022308A1 (it)	2004-04-30	Proteine per il trattamento di neutropenie.